Rare Thyroid Therapeutics is a privately held, clinical stage research and development company, located in Stockholm, Sweden. We are specialized in the development of therapies for rare thyroid signalling disorders, a disease area which is currently underserved and where there is a significant unmet medical need, without available therapies. Our team holds considerable experience from the rare and orphan space and have been involved in several successful companies and development projects within the field, including Swedish Orphan (Sobi), Medical Need and Wilson Therapeutics.

Our collaboration with Erasmus Medical Center in Rotterdam to develop the first cure for MCT8 deficiency was in 2017 selected for an EU grant within the EUREKA EUROSTARS framework

Our Team

Peder Walberg

Peder Walberg, CEO and Director of the Board

Peder holds extensive experience from development and commercialization of orphan drugs, both on an operative and board level. His background includes being the founder and CEO of Medical Need Europe and EVP Business Development and Strategy at Sobi and Swedish Orphan. He also served as Nordic Head of New Products and BD&L at Novartis. Peder has a long track-record from successfully identifying and partnering niche and orphan assets. He has previously served as a director of the board of Wilson Therapeutics and OxThera and is currently on the board of Immedica. Peder is a registered physician with an MD from Uppsala University, a BSc in International Economics and Business Administration from the same university and has a background as a management consultant with the Boston Consulting Group, focusing primarily on the life sciences sector.

Kennet Rooth

Kennet Rooth, Chairman of the Board of Directors

Kennet has long experience from launching and marketing niche specialty pharmaceuticals and orphan drugs. Kennet served as the CEO of Swedish Orphan Biovitrum (Sobi) and was prior to that Head of Marketing and Sales and deputy CEO of Swedish Orphan International, with responsibility for the international expansion and establishment of subsidiaries in several European countries. Kennet held various positions within Bristol-Myers Squibb both in Sweden and internationally, including Executive Director CNS EMENA, Country manager, Business Unit Manager and Product Manager. He was also a member of the global development and commercialization team for Abilify. Kennet holds a degree in Science from Stockholm University and received general management training at INSEAD.

Gudrun Hörnquist

Gudrun Hörnquist, Director of the Board

Gudrun has a long career within the regulatory field, including the Swedish Medicinal Products Agency where she gained experience from named patient use and marketing authorization approvals and procedures. Gudrun served as Head of Regulatory and Quality Affairs at Swedish Orphan International for over fifteen years, where she through her responsibility for the company's regulatory activities gained significant experience from the registration and regulatory maintenance of niche pharmaceuticals and orphan medicinal products in both EU and other territories. Gudrun holds a Pharm. Mag. from Uppsala University.